Months after launching with lofty goal, Flagship startup streamlines ops, chops headcount

Amber Tong

Even by Flagship Pioneering’s standards, the stated goal at Vesalius Therapeutics — unveiled at its launch this March — was exceedingly ambitious. Armed with $75 million …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Months after launching with lofty goal, Flagship startup streamlines ops, chops headcount

Amber Tong

Sign up to read this article for free.

FDA approves subcutaneous version of Bristol Myers' Opdivo

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

WuXi AppTec will sell cell and gene therapy business to private equity firm

Sofinnova outlines $550M fund after IPOs and M&A deals

CMS explains what went into its first round of drug price negotiations

Months af­ter launch­ing with lofty goal, Flag­ship start­up stream­lines ops, chops head­count

Amber Tong

Sign up to read this article for free.

more like this

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Months after launching with lofty goal, Flagship startup streamlines ops, chops headcount

FDA approves subcutaneous version of Bristol Myers' Opdivo

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

WuXi AppTec will sell cell and gene therapy business to private equity firm

Sofinnova outlines $550M fund after IPOs and M&A deals

CMS explains what went into its first round of drug price negotiations